In Vivo CAR-T Strategic Market Update And Manufacturing Implications For CDMO Partners

By Clemens Jakobi, Senior Director, Commercial Development, Specialized Modalities, and Suparna Sanyal, Director of Commercial Development, Viral Vectors, Specialized Modalities

Large biopharma has spent heavily on in vivo CAR-T since 2025, buying delivery platforms and teams before any technical approach has won out. With CAR biology largely validated ex vivo, the contest has moved to delivery, and manufacturing is where that contest is increasingly decided.

Authors Clemens Jakobi and Suparna Sanyal of Lonza map the deal landscape and the clinical programs across lentiviral and mRNA-LNP modalities. They also examine how complexity is redistributed rather than removed, and why analytics, immunogenicity, and safety questions land earlier in CMC than many sponsors expect. The paper also looks at what sponsors now ask of development partners, and why integration may matter more than any single technical step.

Explore the analysis to see where the pressure points sit.